Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.
作者信息
Harris Emily
出版信息
JAMA. 2023 Jul 25;330(4):306. doi: 10.1001/jama.2023.12055.
PMID:37405802
Abstract
摘要
相似文献
1
Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.三联激素组合药物瑞他鲁肽可使体重减轻24%。
JAMA. 2023 Jul 25;330(4):306. doi: 10.1001/jama.2023.12055.
2
Triple-Hormone-Receptor Agonist Retatrutide for Obesity.用于治疗肥胖症的三激素受体激动剂瑞他鲁肽
N Engl J Med. 2023 Oct 26;389(17):1628. doi: 10.1056/NEJMc2310645.
3
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?胰高血糖素样肽-1（GLP-1）、葡萄糖依赖性促胰岛素多肽（GIP）和胰高血糖素受体激动剂 retatrutide（LY3437943）在糖尿病和肥胖症的治疗方面是否向前迈进了一步？
Expert Opin Investig Drugs. 2023 May;32(5):355-359. doi: 10.1080/13543784.2023.2206560. Epub 2023 Apr 24.
4
Triple-Hormone-Receptor Agonist Retatrutide for Obesity.用于治疗肥胖症的三激素受体激动剂瑞他鲁肽
N Engl J Med. 2023 Oct 26;389(17):1629. doi: 10.1056/NEJMc2310645.
5
Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.用于治疗肥胖症的三激素受体激动剂瑞他鲁肽。回复。
N Engl J Med. 2023 Oct 26;389(17):1629-1630. doi: 10.1056/NEJMc2310645.
6
Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.三期临床试验：艾塞那肽/二甲双胍/预混胰岛素类似物（双时相）治疗 2 型糖尿病的疗效和安全性
Am J Ther. 2018 Nov/Dec;25(6):e609-e616. doi: 10.1097/MJT.0000000000000431.
7
Combination treatment to CONQUER obesity?
Lancet. 2011 Apr 16;377(9774):1295-7. doi: 10.1016/S0140-6736(11)60518-7.
8
Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
Int J Clin Pract. 2010 Oct;64(11):1462-1465. doi: 10.1111/j.1742-1241.2010.02501.x.
9
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.氯卡色林、芬特明-托吡酯组合及纳曲酮-安非他酮组合用于减肥：区分这些药物的15分钟挑战
Int J Clin Pract. 2014 Dec;68(12):1401-5. doi: 10.1111/ijcp.12587.
10
Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.纳曲酮 + 安非他酮（Mysimba）。仅为适度减重使用风险过高。
Prescrire Int. 2015 Oct;24(164):229-33.
引用本文的文献
1
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.胰高血糖素样肽-1 受体：作用机制与治疗进展。
Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z.
2
Clinical and Therapeutic Implications of Male Obesity.男性肥胖的临床及治疗意义
J Clin Med. 2023 Aug 17;12(16):5354. doi: 10.3390/jcm12165354.
Zotero 插件